Pro-social and pro-cognitive effects of LIT-001, a novel oxytocin receptor agonist in a neurodevelopmental model of schizophrenia

被引:3
|
作者
Piotrowska, Diana [1 ]
Potasiewicz, Agnieszka [1 ]
Popik, Piotr [1 ]
Nikiforuk, Agnieszka
机构
[1] Polish Acad Sci, Dept Behav Neurosci & Drug Dev, Maj Inst Pharmacol, Krakow, Poland
关键词
Schizophrenia; Cognitive impairments; Social withdrawal; Social interaction; Ultrasonic vocalisation; Oxytocin; ULTRASONIC VOCALIZATIONS; OBJECT RECOGNITION; RATS; BEHAVIOR; DEFICITS; MEMORY; NEUROGENESIS; DISRUPTION; ANXIETY; REWARD;
D O I
10.1016/j.euroneuro.2023.09.005
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Social and cognitive dysfunctions are the most persistent symptoms of schizophrenia. Since oxytocin (OXT) is known to play a role in social functions and modulates cognitive processes, we investigated the effects of a novel, nonpeptide, selective OXT receptor agonist, LIT-001, in a neurodevelopmental model of schizophrenia. Administration of methylazoxymethanol acetate (MAM; 22 mg/kg) on the 17th day of rat pregnancy is known to cause developmental disturbances of the brain, which lead to schizophrenia-like symptomatology in the offspring. Here, we examined the effects of acutely administered LIT-001 (1, 3, and 10 mg/kg) in MAM-exposed males and females on social behaviour, communication and cognition. We report that MAMtreated adult male and female rats displayed reduced social behaviour, ultrasonic communication and novel object recognition test performance. LIT-001 partially reversed these deficits, increasing the total social interaction time and the number of 'positive', highly-modulated 50 kHz ultrasonic calls in male rats. The compound ameliorated MAM-induced deficits in object discrimination in both sexes. Present results confirm the pro-social activity of LIT-001 and demonstrate its pro-cognitive effects following acute administration.(c) 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页码:30 / 42
页数:13
相关论文
共 50 条
  • [1] LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism
    Frantz, Marie-Celine
    Pellissier, Lucie P.
    Pflimlin, Elsa
    Loison, Stephanie
    Gandia, Jorge
    Marsol, Claire
    Durroux, Thierry
    Mouillac, Bernard
    Becker, Jerome A. J.
    Le Merrer, Julie
    Valencia, Christel
    Villa, Pascal
    Bonnet, Dominique
    Hibert, Marcel
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (19) : 8670 - 8692
  • [2] Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects
    Zajdel, Pawel
    Kos, Tomasz
    Marciniec, Krzysztof
    Satala, Grzegorz
    Canale, Vittorio
    Kaminski, Krzysztof
    Holuj, Malgorzata
    Lenda, Tomasz
    Koralewski, Robert
    Bednarski, Marek
    Nowinski, Leszek
    Wojcikowski, Jacek
    Daniel, Wladyslawa A.
    Nikiforuk, Agnieszka
    Nalepa, Irena
    Chmielarz, Piotr
    Kusmierczyk, Justyna
    Bojarski, Andrzej J.
    Popik, Piotr
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 145 : 790 - 804
  • [3] Blockade of pro-cognitive effects of angiotensin IV and physostigmine in mice by oxytocin antagonism
    Gard, Paul R.
    Naylor, Cathy
    Ali, Sofiya
    Partington, Clare
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2012, 683 (1-3) : 155 - 160
  • [4] Pro-cognitive effects of a Nociceptin/orphaninFQ receptor antagonist in a mouse model of chronic stress
    Da Silva, F. D'oliveira
    Harster, A.
    Fabiola, S.
    Lopez, S.
    Rampon, C.
    Mouledous, L.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 53 : S585 - S586
  • [5] Pro-Cognitive and Antipsychotic Efficacy of the α7 Nicotinic Partial Agonist SSR180711 in Pharmacological and Neurodevelopmental Latent Inhibition Models of Schizophrenia
    Segev Barak
    Michal Arad
    Amaya De Levie
    Mark D Black
    Guy Griebel
    Ina Weiner
    Neuropsychopharmacology, 2009, 34 : 1753 - 1763
  • [6] The importance of pro-social processing, and ameliorating dysfunction in schizophrenia. An FMRI study of oxytocin
    Wigton, Rebekah
    Tracy, Derek K.
    Verneuil, Tess M.
    Johns, Michaela
    White, Thomas
    Michalopoulou, Panayiota G.
    Averbeck, Bruno
    Shergill, Sukhwinder
    SCHIZOPHRENIA RESEARCH-COGNITION, 2022, 27
  • [7] Pro-Cognitive and Antipsychotic Efficacy of the α7 Nicotinic Partial Agonist SSR180711 in Pharmacological and Neurodevelopmental Latent Inhibition Models of Schizophrenia
    Barak, Segev
    Arad, Michal
    De Levie, Amaya
    Black, Mark D.
    Griebel, Guy
    Weiner, Ina
    NEUROPSYCHOPHARMACOLOGY, 2009, 34 (07) : 1753 - 1763
  • [8] SEN12333/WAY-317538, a novel pro-cognitive and neuroprotective α7 nicotinic receptor agonist
    Comery, T. A.
    Scali, C.
    Haydar, S.
    Roncarati, R.
    Ghiron, C.
    Dunlop, J.
    Aschmies, S.
    Bothmann, H.
    Graf, R.
    Gianfriddo, M.
    Grauer, S.
    Jow, B.
    Kelley, C.
    Terstappen, G.
    BIOCHEMICAL PHARMACOLOGY, 2007, 74 (08) : SMA30 - SMA30
  • [9] The sleep deprivation model of cognitive impairment and the effects of the pro-cognitive drug, donepezil
    Dodds, C.
    Bullmore, E.
    O'Neil, B.
    Miller, S.
    Henson, R.
    Smith, M.
    Lawrence, P.
    Swirski, B.
    Nathan, P.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 44 - 44
  • [10] THE SLEEP DEPRIVATION MODEL OF COGNITIVE IMPAIRMENT AND THE EFFECTS OF THE PRO-COGNITIVE DRUG, DONEPEZIL
    Dodds, C. M.
    Bullmore, E. T.
    Miller, S.
    Henson, R.
    Smith, M.
    Lawrence, P.
    Swirski, B.
    Nathan, P. J.
    JOURNAL OF PSYCHOPHARMACOLOGY, 2010, 24 : A69 - A69